Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 4Completed 3Unknown 2Recruiting 2Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Lymphoma, Large B-Cell, Diffuse 28Multiple Myeloma 26Lymphoma 26Lymphoma, Non-Hodgkin 21Leukemia, Myeloid, Acute 21Leukemia, Lymphocytic, Chronic, B-Cell 21Neoplasms 20Myelodysplastic Syndromes 19Lymphoma, Follicular 18Recurrence 16Lymphoma, B-Cell 16Leukemia 16Burkitt Lymphoma 16Lymphoma, Mantle-Cell 15Triple Negative Breast Neoplasms 14Ovarian Neoplasms 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12Neuroblastoma 10Lymphoma, B-Cell, Marginal Zone 10Hodgkin Disease 10Sarcoma 8Melanoma 8Medulloblastoma 8Rhabdomyosarcoma 7Myeloproliferative Disorders 7Leukemia, Biphenotypic, Acute 7Carcinoma, Non-Small-Cell Lung 6Brain Neoplasms 6

Interventions

fludarabine 1Radiation 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Liposarcoma, Myxoid × Cyclophosphamide × Clear all
NCT03967223 2026-04-17

IGNYTE-ESO

USWM, LLC (dba US WorldMeds)

Phase 2 Active not recruiting
103 enrolled
Sarcoma

Neoplasms, Sarcoma, Synovial, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡